Belpointe Asset Management’s Co-Diagnostics CODX Stock Holding History

Belpointe Asset Management’s Portfolio CODX Stock Details CODX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-17	Closed	-$753	–	1105
2023 Q1	$753	Hold	17	–	–	﹤0.01%	3526
2022 Q4	$1.28K	Buy	+17	New	+$1.59K	﹤0.01%	3388

Other funds holding CODX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

KOC

Koss-Olinger Consulting Gainesville, Florida $1.19B AUM 15.91% 1-Year Est. Return

Belpointe Asset Management's CODX Position: Q2 2023 in Review

Belpointe Asset Management sold out of Co-Diagnostics (CODX) in Q2 2023, closing a stake of 17 shares — an estimated $753 sold.

Belpointe Asset Management first reported a position in CODX in Q4 2022 and held it in 2 quarters. The position peaked at $1.28K in Q4 2022. 43 funds tracked by Wall St. Rank hold CODX as of Q2 2023.

Belpointe Asset Management reported no remaining Co-Diagnostics position as of Q2 2023 after selling out during the quarter.
Belpointe Asset Management sold 17 Co-Diagnostics shares in Q2 2023, an estimated $753.
Belpointe Asset Management first reported a position in Co-Diagnostics in Q4 2022 and held it in 2 quarters.
Belpointe Asset Management's Co-Diagnostics position peaked at $1.28K in Q4 2022.
43 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.